RxDoctor Payments Data

Jessica Kwak

Family · Palos Park, ILNPI 1619661063

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $575, 2.3 times the $249 reported in 2023.

$1,035in general payments, 2019–2025

Across 64 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$192
  • Pfizer$167
  • Amgen$131
  • Actelion Pharmaceuticals US, Inc.$101
  • Novartis$93
  • E.r. Squibb & Sons, L.L.C.$78
  • plus $274 from 11 others

What the payments were for

  • Food & beverage$1,035100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,035 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois →

Medicare billing

Part B allowed, 2024
$5,436
Medicare patients
47
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan12$16,036
JardianceEmpagliflozin17$14,089
Metoprolol Succinate20$415
Amlodipine Besylate33$360
Atorvastatin Calcium18$316
Warfarin Sodium26$257
Losartan Potassium19$214
Hydralazine Hcl26$212
Rosuvastatin Calcium15$180
Spironolactone25$175
Metoprolol Tartrate13$170
Carvedilol28$161
Furosemide29$132
Lisinopril13$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$93$16,03612 claims
Boehringer IngelheimJardiance$41$14,08917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,941 family providers in Illinois.

Other family in Palos Park

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →